1. C-MET can be amplified in multiple tumors such as ovarian,breast,lung, thyroid, Gastric, pancreatic, colorectal and is an independent assessment factor of poor prognosis.
2. In non-small cell lung cancer, C-MET gene amplification was closely associated with poor prognosis and EGFR-TKIS resistance (seen in 11-22% of cases).
3.C-MET gene amplification is one of the targets of Crizotinib. In patients with C-MET gene amplification, tumor size can be significantly reduced after a period of treatment.